VIENNA (MedPage Today) -- Survival failed to improve in patients with heavily treated non-small cell lung cancer who received sorafenib, but the drug did offer advantages in disease control and other outcomes, investigators reported here. via MedPageToday.com - medical news plus CME for physicians Read More Here..
No comments:
Post a Comment